Clinical Trial Update: Scleroderma Lung Disease [Phase 3]

View source ↗

Summary

Phase 3 trial for systemic sclerosis–associated lung disease has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Fibrosis
• Systemic Sclerosis

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Lung Diseases, Pulmonary Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2015-03-06